A cohort study of MPN patients and analysis of bone marrow-derived DNA from different disease stages have consistently shown that MPL W515L and JAK2 V617F co-occur in MPNs, suggesting that these mutations may complement each other in driving MPN pathogenesis (171). The gene discussed is JAK2; the disease is myeloproliferative neoplasm.